For: | Zhuang L, You J, Tang BZ, Ding SY, Yan KH, Peng D, Zhang YM, Zhang L. Preliminary results of Thymosin-a1 vs interferon-α treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B. World J Gastroenterol 2001; 7(3): 407-410 [PMID: 11819800 DOI: 10.3748/wjg.v7.i3.407] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v7/i3/407.htm |
Number | Citing Articles |
1 |
A. Ciancio, M. Rizzetto. Thymalfasin in the treatment of hepatitis B and C. Annals of the New York Academy of Sciences 2010; 1194(1): 141 doi: 10.1111/j.1749-6632.2010.05487.x
|
2 |
S. Iino, J. Toyota, H. Kumada, K. Kiyosawa, S. Kakumu, M. Sata, H. Suzuki, E. B. Martins. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. Journal of Viral Hepatitis 2005; 12(3): 300 doi: 10.1111/j.1365-2893.2005.00633.x
|
3 |
C. Trépo, F. Zoulim. Traitement de l’hépatite B : progrès attendus. Gastroentérologie Clinique et Biologique 2009; 33(8-9): 811 doi: 10.1016/j.gcb.2009.04.005
|
4 |
Xiaoning Wu, Jidong Jia, Hong You. Thymosin alpha-1 treatment in chronic hepatitis B. Expert Opinion on Biological Therapy 2015; 15(sup1): 129 doi: 10.1517/14712598.2015.1007948
|
5 |
Hong-Lei Han, Zhen-Wei Lang. Changes in serum and histology of patients with chronic hepatitis B after interferon alpha-2b treatment. World Journal of Gastroenterology 2003; 9(1): 117-121 doi: 10.3748/wjg.v9.i1.117
|
6 |
Stephanos J Hadziyannis, George V Papatheodoridis. Emerging treatments in chronic hepatitis B. Expert Opinion on Emerging Drugs 2004; 9(2): 207 doi: 10.1517/14728214.9.2.207
|
7 |
Bo Hyun Kim, Youn-Jae Lee, Won Kim, Jung-Hwan Yoon, Eun Uk Jung, Sung Jae Park, Yoon Jun Kim, Hyo-Suk Lee. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: A prospective, multicenter, randomized, open-label study. Scandinavian Journal of Gastroenterology 2012; 47(8-9): 1048 doi: 10.3109/00365521.2012.694902
|
8 |
Haipeng Zhu, Ke Wang, Wei Du, Huanhuan Cao, Qingyang Zhong, Sichun Yin, Jianbo Zhong, Fawu Li. H3K9 acetylation modification and TLR9 immune regulation mechanism in patients after anti-HBV treatment. Medicine 2022; 101(52): e32431 doi: 10.1097/MD.0000000000032431
|
9 |
WANHU FAN, JUN CHENG, SHULIN ZHANG, XIAOJING LIU. Cloning and functions of the HBxAg-binding protein XBP1. Molecular Medicine Reports 2013; 7(2): 618 doi: 10.3892/mmr.2012.1232
|
10 |
Ying Chen, Johnny Sze, Ming-Liang He. HBV cccDNA in patients’ sera as an indicator for HBV reactivation and an early signal of liver damage. World Journal of Gastroenterology 2004; 10(1): 82-85 doi: 10.3748/wjg.v10.i1.82
|
11 |
Yu-Hu Song, Ju-Sheng Lin, Nan-Zhi Liu, Xin-Juan Kong, Na Xie, Nan-Xia Wang, You-Xin Jin, Kuo-Huan Liang. Anti-HBV hairpin ribozyme-mediated cleavage of target RNA <italic>in vitro</italic>. World Journal of Gastroenterology 2002; 8(1): 91-94 doi: 10.3748/wjg.v8.i1.91
|
12 |
E. GARACI, C. FAVALLI, F. PICA, P. SINIBALDI VALLEBONA, A. TERESA PALAMARA, C. MATTEUCCI, P. PIERIMARCHI, A. SERAFINO, A. MASTINO, F. BISTONI, L. ROMANI, G. RASI. Thymosin Alpha 1: From Bench to Bedside. Annals of the New York Academy of Sciences 2007; 1112(1): 225 doi: 10.1196/annals.1415.044
|
13 |
Yong-Feng Yang, Wei Zhao, Yan-Dan Zhong, Yi-Jun Yang, Ling Shen, Ning Zhang, Ping Huang. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: A meta-analysis. Antiviral Research 2008; 77(2): 136 doi: 10.1016/j.antiviral.2007.10.014
|
14 |
Raymund R. Razonable, James M. McGill. Hepatitis Prevention and Treatment. 2004; : 175 doi: 10.1007/978-3-0348-7903-3_10
|
15 |
Chun-Hong Ma, Wen-Sheng Sun, Pei-Kun Tian, Li-Fen Gao, Su-Xia Liu, Xiao-Yan Wang, Li-Ning Zhang, Ying-Lin Cao, Li-Hui Han, Xiao-Hong Liang. A novel HBV antisense RNA gene delivery system targeting hepatocellular carcinoma. World Journal of Gastroenterology 2003; 9(3): 463-467 doi: 10.3748/wjg.v9.i3.463
|
16 |
Yui-Jie Bai, Jin-Rong Zhao, Guan-Ting Lv, Wen-Hong Zhang, Yan Wang, Xiao-Jun Yan. Rapid and high throughput detection of HBV YMDD mutants with fluorescence polarization. World Journal of Gastroenterology 2003; 9(10): 2344-2347 doi: 10.3748/wjg.v9.i10.2344
|
17 |
Xiao-Ju Guan, Xiao-Jun Guan, Yu-Zhang Wu, Zheng-Cai Jia, Tong-Dong Shi, Yan Tang. Construction and characterization of an experimental ISCOMS-based hepatitis B polypeptide vaccine. World Journal of Gastroenterology 2002; 8(2): 294-297 doi: 10.3748/wjg.v8.i2.294
|
18 |
YUN-FAN LIAW. Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B. Journal of Gastroenterology and Hepatology 2004; 19(S6): S73 doi: 10.1111/j.1440-1746.2004.03633.x
|
19 |
Roberto Camerini, Enrico Garaci. Historical review of thymosin α 1 in infectious diseases. Expert Opinion on Biological Therapy 2015; 15(sup1): 117 doi: 10.1517/14712598.2015.1033393
|
20 |
Murat Saruc, Nuri Ozden, Nurten Turkel, Semin Ayhan, Lynette M. Hock, Isil Tuzcuoglu, Hakan Yuceyar. Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. Journal of Pharmaceutical Sciences 2003; 92(7): 1386 doi: 10.1002/jps.10401
|
21 |
Jin Ding, Jun Liu, Cai-Fang Xue, Wei-Dong Gong, Ying-Hui Li, Ya Zhao. Anti-HBV effect of TAT- HBV targeted ribonuclease. World Journal of Gastroenterology 2003; 9(7): 1525-1528 doi: 10.3748/wjg.v9.i7.1525
|
22 |
Guo-Liang Zhang, Ye-Hong Wang, Wei Ni, Hui-Ling Teng, Zhi-Bin Lin. Hepatoprotective role of <italic>ganoderma lucidum</italic> polysaccharide against BCG-induced immune liver injury in mice. World Journal of Gastroenterology 2002; 8(4): 728-733 doi: 10.3748/wjg.v8.i4.728
|
23 |
Rong-Nan Chien, Yun-Fan Liaw. Thymalfasin for the treatment of chronic hepatitis B. Expert Review of Anti-infective Therapy 2004; 2(1): 9 doi: 10.1586/14787210.2.1.9
|
24 |
Zheng-Wen Liu, Qun-Ying Han, Ni Zhang, Wen Kang. Sequential changes of serum ferritin levels and their clinical significance in lamivudine-treated patients with chronic viral hepatitis B. World Journal of Gastroenterology 2004; 10(7): 972-976 doi: 10.3748/wjg.v10.i7.972
|
25 |
R-N. Chien, C-Y. Lin, C-T. Yeh, Y-F. Liaw. Hepatitis B virus genotype B is associated with better response to thymosin ?1 therapy than genotype C. Journal of Viral Hepatitis 2006; 13(12): 845 doi: 10.1111/j.1365-2893.2006.00761.x
|